Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 62, Issue 12, Pages 1372-1378Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-005-4473-0
Keywords
LDL-cholesterol; apoB truncation; genetics; lipoprotein metabolism; non-alcoholic fatty liver
Categories
Funding
- NHLBI NIH HHS [HL-R01-59515, HL-R37-46420] Funding Source: Medline
Ask authors/readers for more resources
Familial hypobetalipoproteinemia (FHBL), an autosomal dominant disorder, is defined as <5th percentile LDL-cholesterol or apolipoprotein (apo) B in the plasma. FHBL subjects are generally heterozygous and asymptomatic. Three genetic forms exist: (i) premature stop codon specifying mutations of APOB; (ii) FHBL linked to a susceptibility locus on the chromosome 3p21; and (iii) FHBL linked neither to APOB nor to the chromosome 3p21. In heterozygous apoB-defective FHBL, the hepatic VLDL export system is defective because apoB 100, the product of the normal allele, is produced at similar to 25% of normal rate, and truncated apoB is cleared too rapidly. The reduced capacity for hepatic triglyceride export increases hepatic fat three-fold. Indexes of adiposity and insulin action are similar to controls. 'Knock-in' mouse models of apoB truncations resemble human FHBL phenotypes. Liver fat in the chromosome 3p21-linked FHBL is normal. Elucidation of the genetic basis of the non-apoB FHBL could uncover attractive targets for lipid-lowering therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available